Armetheon inks $24.3 mln Series B
San Francisco Bay area-based Armetheon, a cardiovascular disease-focused biopharmaceutical company, has raised $24.3 million in Series B funding. Hercules Bioventure Partners and Capital TEN II led the round. Locust Walk Securities advised Armetheon on the transaction. Also, Dr. Larry Hsu has been added to Armetheon's board of directors.
5 February 2015•3 mins read
